GPC3 CAR Lentivirus

Our GPC3 CAR Lentivirus, which targets the GPC3 gene linked to hepatocellular carcinoma, is an example of our commitment to delivering fresh approaches to the management of difficult-to-treat cancers.

Check the CAR-T Cell Preparation-Lentivirus Packaging Service

Order information

Description

At GeneMedi we are committed to expanding cellular knowledge of cancer therapy with our GPC3 CAR Lentivirus, with glypican-3 (GPC3) being a cell surface proteoglycan strongly overexpressed in HCC. HCC is the most common type of liver cancer, which is generally diagnosed at an advanced stage and has remarkable resistance to several treatment approaches. There is a desperate need for such new therapeutic strategies, and GPC3 is a rational target of such experimental therapies due to its low expression level in normal adult tissues which should minimize side effects. Our GPC3 CAR design has integrated not only the high affinity scFv against GPC3 but also combined structural and signaling motifs to boost T cell activation, proliferation, and survival. We use state-of-art molecular engineering to optimize the therapeutic ratio of these CAR-T cells without compromising the efficacy to the core: Our focus is the safety of such cells and preventing toxicity.

During the development of our GPC3 CAR Lentivirus we adhere to strict scientific research and advancements. We have then tried to decipher few of the complexities of HCC tumor microenvironment and the immune escape ways adopted by the tumor cells. For this reason, knowledge of the tumor microenvironment has been used in designing CAR constructs that are effective not only against cancer cells but also immune to the countermeasures offered by the tumor. In addition, GeneMedi’s GPC3 CAR-T cells are constructed for stability within the hepatic environment which typically abnormally suppress the engineered immune cells because of immunosuppressive elements present there.

It is among the GPC3 CAR Lentivirus that GeneMedi has for the provision of HCC treatment solutions. Apart from vector supply, we offer full-service in vitro and in vivo preclinical services such as efficacy and toxicity, pharmacokinetics/pharmacodynamics, and first-in-human dose seeking. We also provide advice on the design of clinical trials such as on the choice of patients and appropriate endpoints should provide timely and scientifically rigorous transition from the bench to the clinic.

Indeed, at GeneMedi, quality, safety, innovation remain the corporate values within focus and perfect example is the GPC3 CAR Lentivirus, as a continuous attempt to provide very best and more importantly responsive to unmet needs patients suffering from some of the most aggressive cancers like HCC included.